



University of Southern Denmark

Macro-TSH

A Diagnostic Challenge

Larsen, Camilla Bøgelund; Petersen, Eva Rabing Brix; Overgaard, Martin; Bonnema, Steen Joop

Published in:
European Thyroid Journal

DOI:
10.1159/000509184

Publication date:
2021

Document version:
Accepted manuscript

Citation for published version (APA):
Larsen, C. B., Petersen, E. R. B., Overgaard, M., & Bonnema, S. J. (2021). Macro-TSH: A Diagnostic Challenge. *European Thyroid Journal*, 10(1), 93–97. <https://doi.org/10.1159/000509184>

Go to publication entry in University of Southern Denmark's Research Portal

Terms of use

This work is brought to you by the University of Southern Denmark.
Unless otherwise specified it has been shared according to the terms for self-archiving.
If no other license is stated, these terms apply:

- You may download this work for personal use only.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying this open access version

If you believe that this document breaches copyright please contact us providing details and we will investigate your claim.
Please direct all enquiries to puresupport@bib.sdu.dk

Macro-TSH - a diagnostic challenge

Authors: Camilla Bøgelund Larsen^{1,2}, Eva Rabing Brix Petersen³, Martin Overgaard^{2,4}, Steen Joop Bonnema^{1,2}

¹Department of Endocrinology, Odense University Hospital, Klørvænget 6, DK-5000 Odense C, Denmark

²Department of Clinical Research, University of Southern Denmark, J.B. Winsløvsvej 19, DK-5000 Odense C

³Department of Clinical Biochemistry and Immunology, Hospital of Southern Jutland, Kresten Philipsens Vej 15, DK-6200 Aabenraa

⁴Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, J.B. Winsløvsvej 4, DK-5000 Odense C

Running title: Macro-TSH

Words for indexing: macro-TSH, analytic errors, gel filtration chromatography

Abstract: 182 words

Manuscript: 1170 words

Number of tables: 0

Number of figures: 3

Corresponding author:

Camilla Bøgelund Larsen, MD,

Department of Endocrinology

Odense University Hospital

Klørvænget 6, DK-5000 Odense C, Denmark

Email: Camilla.Bogelund.Larsen@rsyd.dk

What Is Known about This Topic?

- Macro-TSH is a rare condition and caused by binding of TSH to other plasma proteins, most often immunoglobulins. This results in falsely elevated TSH measurement.
- The biochemical profile mimics subclinical hypothyroidism and may lead to inappropriate LT4 treatment.
- No immunoassay can reveal the presence of macro-TSH. Gel filtration chromatography is the state-of-art method for detection of macro-TSH.

What Does This Case Report Add?

- This report highlights the importance of screening for macro-TSH, in addition to other analytical problems, in patients with a markedly and isolated elevated plasma TSH, particularly if other signs of thyroid dysfunction are absent.

Abstract

Introduction

Analytical problems should be considered in case of a discrepancy between the results of biochemical tests and the clinical findings. Macro-hormones often artefactually elevate biochemical tests.

Case presentation

A young male was referred with persistently elevated TSH (148 mIU/L) measured by a sandwich electrochemi-luminescence immunoassay, ECLIA (Cobas, Roche, Basel, Switzerland). The patient's complaints were unspecific, and he appeared clinically euthyroid. The plasma levels of free T4 and free T3 were within the normal range, thyroid autoantibodies were negative, and thyroid ultrasonography was normal. During a short trial of thyroid hormone substitution, the level of TSH decreased to near-normal levels, but hyperthyroid symptoms emerged. TSH analysed by a different immunoassay (Architect, Abbott, Chicago, Illinois, USA) yielded similar results. In addition, serial dilutions were performed showing linearity, without detection of heterophilic antibody interference. Gel filtration chromatography confirmed the presence of macro-TSH.

Conclusion

The patient harboured macro-TSH, which is a rare condition. The complex binding of TSH to other plasma proteins, most often immunoglobulins, results in elevated plasma TSH. However, the biologically active fraction of TSH is normal, reflected by clinical and biochemical euthyroidism.

58 **Introduction**

59 Despite methodological improvements, immunoassays used for evaluation of the thyroid
60 function are still exposed to different types of interferences. Macro-thyrotropin (macro-TSH) is
61 caused by a large amount of monomeric TSH complexed with anti-TSH antibodies – mostly
62 immunoglobulin G (1, 2). Macro-hormones, including macro-TSH, are considered biologically
63 inactive, and only a small fraction of the total amount of TSH in plasma remains free (3).

64 Although being bound into such complexes, TSH is still detected by the current assays used for
65 TSH measurement, causing elevated results. Thus, none of the commercially available immunoassays
66 employed for TSH testing can discriminate macro-TSH from the bioactive freely circulating TSH. In
67 patients harbouring macro-TSH, the falsely elevated TSH may lead to clinical mismanagement.
68 Macro-TSH is a rare condition, with a reported prevalence ranging from 0.6% to 1.6% (4-6). Here,
69 we present a case with isolated TSH elevation, illustrating the challenges of diagnosing macro-TSH.

70

71 **Case presentation**

72 A 29-year-old male was referred from a local hospital with persistently elevated TSH (148
73 mU/L) measured by a sandwich electrochemi-luminescence-immunoassay (ECLIA) on Cobas 8000
74 (Roche, Basel, Switzerland). The patient's complaints were unspecific of nature, like tiredness,
75 headache, dizziness, and discomfort in the chest. Plasma levels of free T4 and free T3 were within
76 the normal range, and thyroid autoantibodies were negative. The physical examination was without
77 abnormal findings, and he appeared clinically euthyroid. Thyroid ultrasonography was normal
78 regarding size, texture and echogenicity. In addition, MRI of the pituitary gland and an ACTH-
79 stimulation test were normal. The symptoms and the increased TSH had prompted a trial of
80 levothyroxine (LT4) replacement therapy on the suspicion of thyroid failure. Up to 150 µg LT4 per
81 day was given. Hereby, plasma TSH decreased to near-normal levels within a few weeks, but
82 hyperthyroid symptoms emerged in parallel with the thyroid hormones rising to supranormal levels
83 (Figure 1). Therefore, the treatment was withdrawn.

84

85 **Supplementary laboratory tests**

86 Measurement of TSH by use of a different immunoassay (Architect, Abbott, Illinois, USA)
87 yielded a similar high TSH level (>100 mIU/L) as did the assay from Roche. Serial dilution of the
88 patient's plasma was analysed using both immunoassays to rule out possible interference from human
89 anti-mouse antibodies targeting TSH assay antibodies. For both assays, linear and almost identical
90 dilution patterns were found (Figure 2A), making interference from heterophilic antibody highly

91 unlikely. Further analyses included search for a mutation in the TSH-receptor-gene and the TSH-
92 beta-gene, also with negative results (7). Plasma TSH in both parents was within the reference range.

93 Thyroid failure was found unlikely, based on the current results, the very high TSH level
94 contrasting the normal levels of FT3 and FT4, as well as the appearance of the patient. The possibility
95 of a complex formation (i.e. macro-TSH) of TSH and an unknown component in the plasma was
96 considered. Therefore, gel filtration chromatography (GFC) was performed on plasma samples from
97 the patient, a control person with slightly elevated TSH, and a pool of healthy controls, respectively
98 (Figure 2B). 100 μ L plasma was fractioned on a Superdex S-75 column (PBS, pH 7.4; 1 mM EDTA)
99 via Äcta FPLC. Fractions of 500 μ L were collected, and TSH was analysed by Cobas 8000 e801
100 (Roche, Basel, Switzerland). The TSH-peak of the control person eluted at 24 kDa, corresponding to
101 free TSH (theoretically 28 kDa), while the patient's TSH-peak eluted at 154 kDa, compatible with a
102 TSH-IgG complex (theoretically 178 kDa). This finding confirmed that the highly elevated plasma
103 TSH was caused by the presence of macro-TSH. Thus, the patient had no thyroid disorder and his
104 symptoms were non-thyroid related.

105

106 *Discussion*

107 Characteristics of patients with macro-TSH include elevated TSH, normal levels of the thyroid
108 hormones, and no clinical symptoms of thyroid dysfunction. Plasma TSH is often markedly increased,
109 like in our patient, but cases with only slightly elevated TSH have been published (5). Biochemically,
110 this mimics subclinical hypothyroidism and may lead to inappropriate LT4 therapy (2). However, a
111 decrease in plasma TSH in response to LT4 therapy cannot exclude the presence of macro-TSH (5,
112 8). As demonstrated in our case, plasma TSH decreased significantly within a few weeks during LT4
113 replacement therapy, reflecting a suppression of TSH secretion of the pituitary gland. This
114 observation seems to indicate that TSH is bound rather weakly to the immunoglobulins and in a state
115 of equilibrium with the free TSH in the circulation. If the complex binding was irreversible, the
116 decline in TSH would probably have been more prolonged, considering the long half-life of
117 immunoglobulins. To a large extent, macro-TSH mimics the situation seen with the thyroid
118 hormones, where only a minor fraction is freely circulating due to protein binding.

119 No routine TSH immunoassay can disclose the presence of macro-TSH. For this purpose, the
120 gold standard method is GFC, which can separate the various TSH fractions according to the
121 molecular weight. There is no clear answer when to screen for macro-TSH. This condition may be
122 more common than hitherto reported. Mills et al. (6) suggested that macro-TSH should be suspected

123 in case of TSH above 10 mUI/L, while Hattori et al. (4) recommended screening for macro-TSH,
124 especially in women of childbearing age in whom LT4 therapy for subclinical hypothyroidism is
125 considered. Since macro-TSH is present in less than 1% in most populations, such an approach is
126 controversial and will significantly increase the costs of thyroid function tests.

127 For screening of macroprolactinemia, polyethylene glycol (PEG) mediated precipitation has
128 been widely adopted by clinical laboratories (9). This method is based on either post-PEG recovery
129 level of monomeric prolactin or the use of post-PEG monomeric prolactin reference intervals.
130 Dilution studies and measurement of TSH after addition of PEG might be helpful in identifying assay
131 interference, without being definitive regarding cause of such interference. Considering lower costs
132 and higher accesibility than with GFC, such an approach may be a valid alternative for detection of
133 macro-TSH, although results must be confirmed by performing GFC (2).

134 The etiology behind the development of macro-TSH is unknown. Likewise, little is known
135 whether macro-TSH may persist lifelong or if it is transient of nature. Apart from jeopardizing the
136 diagnostic process, the presence of macro-TSH is probably of no harm to the patient. Nevertheless,
137 it may be considered to follow the patients regularly, in order to gain more knowledge about this
138 condition (1, 10).

139 In conclusion, macro-TSH, in addition to other analytic interferences, should always be
140 considered in patients with a markedly and isolated elevated plasma TSH, particularly if other signs
141 of thyroid dysfunction are absent.

142

143 **Acknowledgement**

144 We want to thank consultant Sevinch Rustamova, MD, who has been involved in the care taking of
145 the patient and Niels Strømvg Larsen for excellent technical assistance.

146

147 **Statement of Ethics**

148 The research was conducted ethically in accordance with the World Medical Association Declaration
149 of Helsinki. The patient gave consent to publication of the case.

150

151 **Disclosure Statement**

152 The authors have no conflicts of interest to declare.

153

154 **Funding Sources**

155 There were no funding sources.

156

157 **Author Contributions**

158 All authors participated in drafting the article or revising it critically for important intellectual content
159 and gave their final approval of the version to be submitted.

160

161 **References**

- 162 1. Hattori N, Ishihara T, Matsuoka N, Saito T, Shimatsu A. Anti-Thyrotropin Autoantibodies in
163 Patients with Macro-Thyrotropin and Long-Term Changes in Macro-Thyrotropin and Serum
164 Thyrotropin Levels. *Thyroid*. 2017;27(2):138-46.
- 165 2. Favresse J, Burlacu MC, Maiter D, Gruson D. Interferences With Thyroid Function
166 Immunoassays: Clinical Implications and Detection Algorithm. *Endocr Rev*. 2018;39(5):830-50.
- 167 3. Hattori N, Aisaka K, Chihara K, Shimatsu A. Current Thyrotropin Immunoassays Recognize
168 Macro-Thyrotropin Leading to Hyperthyrotropinemia in Females of Reproductive Age. *Thyroid*.
169 2018;28(10):1252-60.
- 170 4. Hattori N, Ishihara T, Shimatsu A. Variability in the detection of macro TSH in different
171 immunoassay systems. *Eur J Endocrinol*. 2016;174(1):9-15.
- 172 5. Hattori N, Ishihara T, Yamagami K, Shimatsu A. Macro TSH in patients with subclinical
173 hypothyroidism. *Clin Endocrinol (Oxf)*. 2015;83(6):923-30.
- 174 6. Mills F, Jeffery J, Mackenzie P, Cranfield A, Ayling RM. An immunoglobulin G complexed
175 form of thyroid-stimulating hormone (macro thyroid-stimulating hormone) is a cause of elevated
176 serum thyroid-stimulating hormone concentration. *Ann Clin Biochem*. 2013;50(Pt 5):416-20.
- 177 7. Stephenson A, Lau L, Eszlinger M, Paschke R. The Thyrotropin Receptor Mutation Database
178 Update. *Thyroid*. 2020. Doi: 10.1089/thy.2019.0807.
- 179 8. Verhoye E, Van den Bruel A, Delanghe JR, Debruyne E, Langlois MR. Spuriously high
180 thyrotropin values due to anti-thyrotropin antibodies in adult patients. *Clin Chem Lab Med*.
181 2009;47(5):604-6.
- 182 9. Overgaard M, Pedersen SM. Serum prolactin revisited: parametric reference intervals and cross
183 platform evaluation of polyethylene glycol precipitation-based methods for discrimination
184 between hyperprolactinemia and macroprolactinemia. *Clin Chem Lab Med*. 2017;55(11):1744-
185 53.
- 186 10. Loh TP, Kao SL, Halsall DJ, Toh SA, Chan E, Ho SC, et al. Macro-thyrotropin: a case report
187 and review of literature. *J Clin Endocrinol Metab*. 2012;97(6):1823-8.

188

189 **Figure Legends**

190 Fig 1: *The response to levothyroxine (LT4) replacement therapy in the patient with macro-TSH.*
191 *Initially, plasma TSH was high but decreased during LT4, in parallel with a rise in plasma free T4.*
192 *Reference interval of TSH: 0.3–4.0 mIU/L; Free T4: 12–21 pmol/L. LT4 was initiated at week=0 and*
193 *withdrawn at week=28.*

194

195 **Fig 2**

196 **A): Serial dilution analyses were made with two different assays (Cobas and Architect), both showing**
197 **similar and normal linear TSH dilution response. The upper limit of measurement in both assays is**
198 **100 mIU/L and undiluted measurements are thus not shown.**

199 *B) Analysis of TSH monomer and macro species in plasma. Plasma (0.1 mL) from the patient (TSH*
200 *case), a control person with slightly elevated TSH, and a pool of healthy controls, respectively, was*
201 *subjected to gel filtration chromatography (GFC), and TSH immunoreactivity was analysed in the*
202 *resulting fractions using the Cobas method. The expected (interpolated) molecular weights (kDa) of*
203 *free TSH and TSH bound to immunoglobulin G (IgG) are indicated by arrows.*

Macro-TSH - a diagnostic challenge

Authors: Camilla Bøgelund Larsen^{1,2}, Eva Rabing Brix Petersen³, Martin Overgaard^{2,4}, Steen Joop Bonnema^{1,2}

¹Department of Endocrinology, Odense University Hospital, Klørvænget 6, DK-5000 Odense C, Denmark

²Department of Clinical Research, University of Southern Denmark, J.B. Winsløvsvej 19, DK-5000 Odense C

³Department of Clinical Biochemistry and Immunology, Hospital of Southern Jutland, Kresten Philipsens Vej 15, DK-6200 Aabenraa

⁴Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, J.B. Winsløvsvej 4, DK-5000 Odense C

Running title: Macro-TSH

Words for indexing: macro-TSH, analytic errors, gel filtration chromatography

Abstract: 182 words

Manuscript: 1170 words

Number of tables: 0

Number of figures: 3

Corresponding author:

Camilla Bøgelund Larsen, MD,

Department of Endocrinology

Odense University Hospital

Klørvænget 6, DK-5000 Odense C, Denmark

Email: Camilla.Bogelund.Larsen@rsyd.dk

What Is Known about This Topic?

- Macro-TSH is a rare condition and caused by binding of TSH to other plasma proteins, most often immunoglobulins. This results in falsely elevated TSH measurement.
- The biochemical profile mimics subclinical hypothyroidism and may lead to inappropriate LT4 treatment.
- No immunoassay can reveal the presence of macro-TSH. Gel filtration chromatography is the state-of-art method for detection of macro-TSH.

What Does This Case Report Add?

- This report highlights the importance of screening for macro-TSH, in addition to other analytical problems, in patients with a markedly and isolated elevated plasma TSH, particularly if other signs of thyroid dysfunction are absent.

Abstract

Introduction

Analytical problems should be considered in case of a discrepancy between the results of biochemical tests and the clinical findings. Macro-hormones often artefactually elevate biochemical tests.

Case presentation

A young male was referred with persistently elevated TSH (148 mIU/L) measured by a sandwich electrochemi-luminescence immunoassay, ECLIA (Cobas, Roche, Basel, Switzerland). The patient's complaints were unspecific, and he appeared clinically euthyroid. The plasma levels of free T4 and free T3 were within the normal range, thyroid autoantibodies were negative, and thyroid ultrasonography was normal. During a short trial of thyroid hormone substitution, the level of TSH decreased to near-normal levels, but hyperthyroid symptoms emerged. TSH analysed by a different immunoassay (Architect, Abbott, Chicago, Illinois, USA) yielded similar results. In addition, serial dilutions were performed showing linearity, without detection of heterophilic antibody interference. Gel filtration chromatography confirmed the presence of macro-TSH.

Conclusion

The patient harboured macro-TSH, which is a rare condition. The complex binding of TSH to other plasma proteins, most often immunoglobulins, results in elevated plasma TSH. However, the biologically active fraction of TSH is normal, reflected by clinical and biochemical euthyroidism.

58 ***Introduction***

59 Despite methodological improvements, immunoassays used for evaluation of the thyroid
60 function are still exposed to different types of interferences. Macro-thyrotropin (macro-TSH) is
61 caused by a large amount of monomeric TSH complexed with anti-TSH antibodies – mostly
62 immunoglobulin G (1, 2). Macro-hormones, including macro-TSH, are considered biologically
63 inactive, and only a small fraction of the total amount of TSH in plasma remains free (3).

64 Although being bound into such complexes, TSH is still detected by the current assays used for
65 TSH measurement, causing elevated results. Thus, none of the commercially available immunoassays
66 employed for TSH testing can discriminate macro-TSH from the bioactive freely circulating TSH. In
67 patients harbouring macro-TSH, the falsely elevated TSH may lead to clinical mismanagement.
68 Macro-TSH is a rare condition, with a reported prevalence ranging from 0.6% to 1.6% (4-6). Here,
69 we present a case with isolated TSH elevation, illustrating the challenges of diagnosing macro-TSH.

70

71 ***Case presentation***

72 A 29-year-old male was referred from a local hospital with persistently elevated TSH (148
73 mU/L) measured by a sandwich electrochemi-luminescence-immunoassay (ECLIA) on Cobas 8000
74 (Roche, Basel, Switzerland). The patient's complaints were unspecific of nature, like tiredness,
75 headache, dizziness, and discomfort in the chest. Plasma levels of free T4 and free T3 were within
76 the normal range, and thyroid autoantibodies were negative. The physical examination was without
77 abnormal findings, and he appeared clinically euthyroid. Thyroid ultrasonography was normal
78 regarding size, texture and echogenicity. In addition, MRI of the pituitary gland and an ACTH-
79 stimulation test were normal. The symptoms and the increased TSH had prompted a trial of
80 levothyroxine (LT4) replacement therapy on the suspicion of thyroid failure. Up to 150 µg LT4 per
81 day was given. Hereby, plasma TSH decreased to near-normal levels within a few weeks, but
82 hyperthyroid symptoms emerged in parallel with the thyroid hormones rising to supranormal levels
83 (Figure 1). Therefore, the treatment was withdrawn.

84

85 ***Supplementary laboratory tests***

86 Measurement of TSH by use of a different immunoassay (Architect, Abbott, Illinois, USA)
87 yielded a similar high TSH level (>100 mIU/L) as did the assay from Roche. Serial dilution of the
88 patient's plasma was analysed using both immunoassays to rule out possible interference from human
89 anti-mouse antibodies targeting TSH assay antibodies. For both assays, linear and almost identical
90 dilution patterns were found (Figure 2A), making interference from heterophilic antibody highly

91 unlikely. Further analyses included search for a mutation in the TSH-receptor-gene and the TSH-
92 beta-gene, also with negative results (7). Plasma TSH in both parents was within the reference range.

93 Thyroid failure was found unlikely, based on the current results, the very high TSH level
94 contrasting the normal levels of FT3 and FT4, as well as the appearance of the patient. The possibility
95 of a complex formation (i.e. macro-TSH) of TSH and an unknown component in the plasma was
96 considered. Therefore, gel filtration chromatography (GFC) was performed on plasma samples from
97 the patient, a control person with slightly elevated TSH, and a pool of healthy controls, respectively
98 (Figure 2B). 100 μ L plasma was fractioned on a Superdex S-75 column (PBS, pH 7.4; 1 mM EDTA)
99 via Äcta FPLC. Fractions of 500 μ L were collected, and TSH was analysed by Cobas 8000 e801
100 (Roche, Basel, Switzerland). The TSH-peak of the control person eluted at 24 kDa, corresponding to
101 free TSH (theoretically 28 kDa), while the patient's TSH-peak eluted at 154 kDa, compatible with a
102 TSH-IgG complex (theoretically 178 kDa). This finding confirmed that the highly elevated plasma
103 TSH was caused by the presence of macro-TSH. Thus, the patient had no thyroid disorder and his
104 symptoms were non-thyroid related.

105

106 ***Discussion***

107 Characteristics of patients with macro-TSH include elevated TSH, normal levels of the thyroid
108 hormones, and no clinical symptoms of thyroid dysfunction. Plasma TSH is often markedly increased,
109 like in our patient, but cases with only slightly elevated TSH have been published (5). Biochemically,
110 this mimics subclinical hypothyroidism and may lead to inappropriate LT4 therapy (2). However, a
111 decrease in plasma TSH in response to LT4 therapy cannot exclude the presence of macro-TSH (5,
112 8). As demonstrated in our case, plasma TSH decreased significantly within a few weeks during LT4
113 replacement therapy, reflecting a suppression of TSH secretion of the pituitary gland. This
114 observation seems to indicate that TSH is bound rather weakly to the immunoglobulins and in a state
115 of equilibrium with the free TSH in the circulation. If the complex binding was irreversible, the
116 decline in TSH would probably have been more prolonged, considering the long half-life of
117 immunoglobulins. To a large extent, macro-TSH mimics the situation seen with the thyroid
118 hormones, where only a minor fraction is freely circulating due to protein binding.

119 No routine TSH immunoassay can disclose the presence of macro-TSH. For this purpose, the
120 gold standard method is GFC, which can separate the various TSH fractions according to the
121 molecular weight. There is no clear answer when to screen for macro-TSH. This condition may be
122 more common than hitherto reported. Mills et al. (6) suggested that macro-TSH should be suspected

123 in case of TSH above 10 mUI/L, while Hattori et al. (4) recommended screening for macro-TSH,
124 especially in women of childbearing age in whom LT4 therapy for subclinical hypothyroidism is
125 considered. Since macro-TSH is present in less than 1% in most populations, such an approach is
126 controversial and will significantly increase the costs of thyroid function tests.

127 For screening of macroprolactinemia, polyethylene glycol (PEG) mediated precipitation has
128 been widely adopted by clinical laboratories (9). This method is based on either post-PEG recovery
129 level of monomeric prolactin or the use of post-PEG monomeric prolactin reference intervals.
130 Dilution studies and measurement of TSH after addition of PEG might be helpful in identifying assay
131 interference, without being definitive regarding cause of such interference. Considering lower costs
132 and higher accessibility than with GFC, such an approach may be a valid alternative for detection of
133 macro-TSH, although results must be confirmed by performing GFC (2).

134 The etiology behind the development of macro-TSH is unknown. Likewise, little is known
135 whether macro-TSH may persist lifelong or if it is transient of nature. Apart from jeopardizing the
136 diagnostic process, the presence of macro-TSH is probably of no harm to the patient. Nevertheless,
137 it may be considered to follow the patients regularly, in order to gain more knowledge about this
138 condition (1, 10).

139 In conclusion, macro-TSH, in addition to other analytic interferences, should always be
140 considered in patients with a markedly and isolated elevated plasma TSH, particularly if other signs
141 of thyroid dysfunction are absent.

142

143 **Acknowledgement**

144 We want to thank consultant Sevinch Rustamova, MD, who has been involved in the care taking of
145 the patient and Niels Strømving Larsen for excellent technical assistance.

146

147 **Statement of Ethics**

148 The research was conducted ethically in accordance with the World Medical Association Declaration
149 of Helsinki. The patient gave consent to publication of the case.

150

151 **Disclosure Statement**

152 The authors have no conflicts of interest to declare.

153

154 **Funding Sources**

155 There were no funding sources.

156

157 **Author Contributions**

158 All authors participated in drafting the article or revising it critically for important intellectual content
159 and gave their final approval of the version to be submitted.

160

161 **References**

- 162 1. Hattori N, Ishihara T, Matsuoka N, Saito T, Shimatsu A. Anti-Thyrotropin Autoantibodies in
163 Patients with Macro-Thyrotropin and Long-Term Changes in Macro-Thyrotropin and Serum
164 Thyrotropin Levels. *Thyroid*. 2017;27(2):138-46.
- 165 2. Favresse J, Burlacu MC, Maiter D, Gruson D. Interferences With Thyroid Function
166 Immunoassays: Clinical Implications and Detection Algorithm. *Endocr Rev*. 2018;39(5):830-50.
- 167 3. Hattori N, Aisaka K, Chihara K, Shimatsu A. Current Thyrotropin Immunoassays Recognize
168 Macro-Thyrotropin Leading to Hyperthyrotropinemia in Females of Reproductive Age. *Thyroid*.
169 2018;28(10):1252-60.
- 170 4. Hattori N, Ishihara T, Shimatsu A. Variability in the detection of macro TSH in different
171 immunoassay systems. *Eur J Endocrinol*. 2016;174(1):9-15.
- 172 5. Hattori N, Ishihara T, Yamagami K, Shimatsu A. Macro TSH in patients with subclinical
173 hypothyroidism. *Clin Endocrinol (Oxf)*. 2015;83(6):923-30.
- 174 6. Mills F, Jeffery J, Mackenzie P, Cranfield A, Ayling RM. An immunoglobulin G complexed
175 form of thyroid-stimulating hormone (macro thyroid-stimulating hormone) is a cause of elevated
176 serum thyroid-stimulating hormone concentration. *Ann Clin Biochem*. 2013;50(Pt 5):416-20.
- 177 7. Stephenson A, Lau L, Eszlinger M, Paschke R. The Thyrotropin Receptor Mutation Database
178 Update. *Thyroid*. 2020. Doi: 10.1089/thy.2019.0807.
- 179 8. Verhoye E, Van den Bruel A, Delanghe JR, Debruyne E, Langlois MR. Spuriously high
180 thyrotropin values due to anti-thyrotropin antibodies in adult patients. *Clin Chem Lab Med*.
181 2009;47(5):604-6.
- 182 9. Overgaard M, Pedersen SM. Serum prolactin revisited: parametric reference intervals and cross
183 platform evaluation of polyethylene glycol precipitation-based methods for discrimination
184 between hyperprolactinemia and macroprolactinemia. *Clin Chem Lab Med*. 2017;55(11):1744-
185 53.
- 186 10. Loh TP, Kao SL, Halsall DJ, Toh SA, Chan E, Ho SC, et al. Macro-thyrotropin: a case report
187 and review of literature. *J Clin Endocrinol Metab*. 2012;97(6):1823-8.

188

189 **Figure Legends**

190 Fig 1: *The response to levothyroxine (LT4) replacement therapy in the patient with macro-TSH.*
191 *Initially, plasma TSH was high but decreased during LT4, in parallel with a rise in plasma free T4.*
192 *Reference interval of TSH: 0.3–4.0 mIU/L; Free T4: 12–21 pmol/L. LT4 was initiated at week=0 and*
193 *withdrawn at week=28.*

194

195 **Fig 2**

196 *A): Serial dilution analyses were made with two different assays (Cobas and Architect), both showing*
197 *similar and normal linear TSH dilution response. The upper limit of measurement in both assays is*
198 *100 mIU/L and undiluted measurements are thus not shown.*

199 *B) Analysis of TSH monomer and macro species in plasma. Plasma (0.1 mL) from the patient (TSH*
200 *case), a control person with slightly elevated TSH, and a pool of healthy controls, respectively, was*
201 *subjected to gel filtration chromatography (GFC), and TSH immunoreactivity was analysed in the*
202 *resulting fractions using the Cobas method. The expected (interpolated) molecular weights (kDa) of*
203 *free TSH and TSH bound to immunoglobulin G (IgG) are indicated by arrows.*





Fig. 2

A.



B.

